Using a large, homogenous patient population, considering each therapeutic context separately, and taking into account the longitudinal availability of various ALK inhibitors for each patient, our study shows that the attrition of ALK+ NSCLC patients between different treatments is approximately 25-30% (Figure 2). Here, ALK is linked to non-small cell lung carcinoma.